---
document_datetime: 2025-12-02 06:25:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/feraccru.html
document_name: feraccru.html
version: success
processing_time: 0.122565
conversion_datetime: 2025-12-24 02:22:49.685019
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Feraccru

[RSS](/en/individual-human-medicine.xml/65551)

##### Authorised

This medicine is authorised for use in the European Union

ferric maltol Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Feraccru](#news-on)
- [More information on Feraccru](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Feraccru is an iron-containing medicine used to treat iron deficiency (lack of iron) in adults.

Feraccru contains the active substance ferric maltol.

Expand section

Collapse section

## How is Feraccru used?

Feraccru is available as capsules (30 mg). The recommended dose is one capsule taken twice a day, morning and evening, on an empty stomach. Treatment duration depends on the severity of the iron deficiency, but generally at least 12 weeks of treatment are required.

The medicine can only be obtained with a prescription.

For more information about using Feraccru, see the package leaflet or contact your doctor or pharmacist.

## How does Feraccru work?

The active substance in Feraccru, ferric maltol, is an iron-containing compound. When taken by mouth, it is absorbed by the cells of the gut; the iron is then released from the compound and transported and stored in the body, helping to restore normal levels in patients with iron deficiency. This helps correct reduced production of haemoglobin (the oxygen-carrying pigment in red blood cells), anaemia (low levels of red blood cells) and any symptoms of the condition. Iron is an essential building block for haemoglobin and the body can produce more haemoglobin and correct anaemia once iron stores are replenished.

## What benefits of Feraccru have been shown in studies?

Feraccru is effective at increasing haemoglobin levels in patients with iron deficiency and anaemia, (defined as haemoglobin levels lower than 12 g/dl for women and 13 g/dl for men).

In a study of 128 patients, those taking Feraccru for 12 weeks had their haemoglobin levels increase on average from 11.0 to 13.2 g/dl whereas in patients taking placebo (a dummy treatment) haemoglobin levels remained at around 11.1 g/dl. In addition, around 65% of patients taking Feraccru achieved normal levels of haemoglobin compared with 10% of those on placebo.

## What are the risks associated with Feraccru?

The most common side effects with Feraccru (which may affect up to 1 in 10 people) are symptoms affecting the gut such as abdominal (belly) pain, flatulence (passing wind), constipation, abdominal discomfort and distension, and diarrhoea; these side effects are usually of mild to moderate intensity.

Severe side effects include abdominal pain, constipation and diarrhoea. For the full list of side effects of Feraccru, see the package leaflet.

Feraccru must not be used in patients with iron overload disorder (haemachromatosis) or in patients receiving repeated blood transfusions. For the full list of restrictions, see the package leaflet.

## Why is Feraccru authorised in the EU?

The European Medicines Agency decided that Feraccru's benefits are greater than its risks and it can be authorised for use in the EU. Feraccru has been shown to be effective in increasing haemoglobin levels in patients with iron deficiency anaemia. Data on how the medicine is absorbed in the body show that Feraccru can also have an effect on patients with iron deficiency who have not already developed anaemia. The safety profile of Feraccru is considered acceptable, with side effects that are mostly mild to moderate in intensity and in line with those of other iron preparations.

## What measures are being taken to ensure the safe and effective use of Feraccru?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Feraccru have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Feraccru are continuously monitored. Side effects reported with Feraccru are carefully evaluated and any necessary action taken to protect patients.

## Other information about Feraccru

Feraccru received a marketing authorisation valid throughout the EU on 18 February 2016.

Feraccru : EPAR - Medicine overview

English (EN) (69.01 KB - PDF)

**First published:** 18/03/2016

**Last updated:** 23/04/2018

[View](/en/documents/overview/feraccru-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-825)

български (BG) (100.63 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/bg/documents/overview/feraccru-epar-medicine-overview_bg.pdf)

español (ES) (74.51 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/es/documents/overview/feraccru-epar-medicine-overview_es.pdf)

čeština (CS) (95.79 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/cs/documents/overview/feraccru-epar-medicine-overview_cs.pdf)

dansk (DA) (72.77 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/da/documents/overview/feraccru-epar-medicine-overview_da.pdf)

Deutsch (DE) (74.17 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/de/documents/overview/feraccru-epar-medicine-overview_de.pdf)

eesti keel (ET) (72.69 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/et/documents/overview/feraccru-epar-medicine-overview_et.pdf)

ελληνικά (EL) (107.15 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/el/documents/overview/feraccru-epar-medicine-overview_el.pdf)

français (FR) (73.96 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/fr/documents/overview/feraccru-epar-medicine-overview_fr.pdf)

hrvatski (HR) (89.94 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/hr/documents/overview/feraccru-epar-medicine-overview_hr.pdf)

italiano (IT) (73.21 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/it/documents/overview/feraccru-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (95.46 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/lv/documents/overview/feraccru-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (96.26 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/lt/documents/overview/feraccru-epar-medicine-overview_lt.pdf)

magyar (HU) (91.53 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/hu/documents/overview/feraccru-epar-medicine-overview_hu.pdf)

Malti (MT) (96.97 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/mt/documents/overview/feraccru-epar-medicine-overview_mt.pdf)

Nederlands (NL) (74.07 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/nl/documents/overview/feraccru-epar-medicine-overview_nl.pdf)

polski (PL) (104.79 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/pl/documents/overview/feraccru-epar-medicine-overview_pl.pdf)

português (PT) (73.48 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/pt/documents/overview/feraccru-epar-medicine-overview_pt.pdf)

română (RO) (93.92 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/ro/documents/overview/feraccru-epar-medicine-overview_ro.pdf)

slovenčina (SK) (95.59 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/sk/documents/overview/feraccru-epar-medicine-overview_sk.pdf)

slovenščina (SL) (90.65 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/sl/documents/overview/feraccru-epar-medicine-overview_sl.pdf)

Suomi (FI) (72.96 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/fi/documents/overview/feraccru-epar-medicine-overview_fi.pdf)

svenska (SV) (73.19 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

23/04/2018

[View](/sv/documents/overview/feraccru-epar-medicine-overview_sv.pdf)

Feraccru : EPAR - Risk-management-plan summary

English (EN) (39.53 KB - PDF)

**First published:** 18/03/2016

**Last updated:** 18/03/2016

[View](/en/documents/rmp-summary/feraccru-epar-risk-management-plan-summary_en.pdf)

## Product information

Feraccru : EPAR - Product Information

English (EN) (2.45 MB - PDF)

**First published:** 18/03/2016

**Last updated:** 18/12/2023

[View](/en/documents/product-information/feraccru-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-330)

български (BG) (3.69 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/bg/documents/product-information/feraccru-epar-product-information_bg.pdf)

español (ES) (2.32 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/es/documents/product-information/feraccru-epar-product-information_es.pdf)

čeština (CS) (2.52 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/cs/documents/product-information/feraccru-epar-product-information_cs.pdf)

dansk (DA) (3.53 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/da/documents/product-information/feraccru-epar-product-information_da.pdf)

Deutsch (DE) (2.62 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/de/documents/product-information/feraccru-epar-product-information_de.pdf)

eesti keel (ET) (2.36 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/et/documents/product-information/feraccru-epar-product-information_et.pdf)

ελληνικά (EL) (2.53 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/el/documents/product-information/feraccru-epar-product-information_el.pdf)

français (FR) (3.72 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/fr/documents/product-information/feraccru-epar-product-information_fr.pdf)

hrvatski (HR) (591.35 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/hr/documents/product-information/feraccru-epar-product-information_hr.pdf)

íslenska (IS) (2.98 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/is/documents/product-information/feraccru-epar-product-information_is.pdf)

italiano (IT) (2.93 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/it/documents/product-information/feraccru-epar-product-information_it.pdf)

latviešu valoda (LV) (3.44 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/lv/documents/product-information/feraccru-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.99 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/lt/documents/product-information/feraccru-epar-product-information_lt.pdf)

magyar (HU) (2.41 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/hu/documents/product-information/feraccru-epar-product-information_hu.pdf)

Malti (MT) (3.07 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/mt/documents/product-information/feraccru-epar-product-information_mt.pdf)

Nederlands (NL) (2.42 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/nl/documents/product-information/feraccru-epar-product-information_nl.pdf)

norsk (NO) (2.95 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/no/documents/product-information/feraccru-epar-product-information_no.pdf)

polski (PL) (10.11 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/pl/documents/product-information/feraccru-epar-product-information_pl.pdf)

português (PT) (2.48 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/pt/documents/product-information/feraccru-epar-product-information_pt.pdf)

română (RO) (2.98 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/ro/documents/product-information/feraccru-epar-product-information_ro.pdf)

slovenčina (SK) (3.48 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/sk/documents/product-information/feraccru-epar-product-information_sk.pdf)

slovenščina (SL) (2.64 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/sl/documents/product-information/feraccru-epar-product-information_sl.pdf)

Suomi (FI) (2.36 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/fi/documents/product-information/feraccru-epar-product-information_fi.pdf)

svenska (SV) (2.93 MB - PDF)

**First published:**

18/03/2016

**Last updated:**

18/12/2023

[View](/sv/documents/product-information/feraccru-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0046/G 15/12/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Feraccru : EPAR - All Authorised presentations

English (EN) (93.2 KB - PDF)

**First published:** 18/03/2016

**Last updated:** 10/02/2022

[View](/en/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-735)

български (BG) (179.99 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/bg/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_bg.pdf)

español (ES) (93.88 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/es/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_es.pdf)

čeština (CS) (180.3 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/cs/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (93.51 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/da/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (93.57 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/de/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (93.23 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/et/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (178.82 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/el/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_el.pdf)

français (FR) (134.09 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/fr/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (180.75 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/hr/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (94.92 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/is/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_is.pdf)

italiano (IT) (93.45 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/it/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (179.43 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/lv/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (180.84 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/lt/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (181.84 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/hu/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (182.54 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/mt/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (93.09 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/nl/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (93.23 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/no/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_no.pdf)

polski (PL) (182.67 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/pl/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_pl.pdf)

português (PT) (93.48 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/pt/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_pt.pdf)

română (RO) (178.08 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/ro/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (182.04 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/sk/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (133.76 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/sl/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (93.04 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/fi/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (93.74 KB - PDF)

**First published:**

18/03/2016

**Last updated:**

10/02/2022

[View](/sv/documents/all-authorised-presentations/feraccru-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Feraccru Active substance ferric maltol International non-proprietary name (INN) or common name ferric maltol Therapeutic area (MeSH) Anemia, Iron-Deficiency Anatomical therapeutic chemical (ATC) code B03AB

### Pharmacotherapeutic group

Antianemic preparations

### Therapeutic indication

Feraccru is indicated in adults for the treatment of iron deficiency.

## Authorisation details

EMA product number EMEA/H/C/002733 Marketing authorisation holder

Norgine B.V.

Antonio Vivaldistraat 150

Opinion adopted 17/12/2015 Marketing authorisation issued 18/02/2016 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Feraccru : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (163.18 KB - PDF)

**First published:** 11/07/2016

**Last updated:** 18/12/2023

[View](/en/documents/procedural-steps-after/feraccru-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Feraccru-H-C-PSUSA-00010476-201808 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/PRAC/501568/2019

English (EN) (116.48 KB - PDF)

**First published:** 03/12/2019

[View](/en/documents/scientific-conclusion/feraccru-h-c-psusa-00010476-201808-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Feraccru-H-C-2733-II-0010 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/172417/2018

English (EN) (1.1 MB - PDF)

**First published:** 23/04/2018

**Last updated:** 23/04/2018

[View](/en/documents/variation-report/feraccru-h-c-2733-ii-0010-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Feraccru

Adopted

Reference Number: EMA/84262/2018

English (EN) (67.75 KB - PDF)

**First published:** 23/02/2018

**Last updated:** 23/02/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-feraccru_en.pdf)

## Initial marketing authorisation documents

Feraccru : EPAR - Public assessment report

Adopted

Reference Number: EMA/14567/2016

English (EN) (2.12 MB - PDF)

**First published:** 18/03/2016

**Last updated:** 18/03/2016

[View](/en/documents/assessment-report/feraccru-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Feraccru

Adopted

Reference Number: EMA/765141/2015

English (EN) (85.1 KB - PDF)

**First published:** 18/12/2015

**Last updated:** 18/12/2015

[View](/en/documents/smop-initial/chmp-summary-opinion-feraccru_en.pdf)

#### News on Feraccru

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2018) 23/02/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 December 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-december-2015) 18/12/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 November 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-november-2015) 20/11/2015

#### More information on Feraccru

- [EMEA-001195-PIP01-11-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001195-pip01-11-m07)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/12/2023

## Share this page

[Back to top](#main-content)